Forum for Science, Industry and Business
  • Sponsored by:
  • Siemens
  • Siemens
  • Siemens
Search our Site:

Topic (optional):

 

Home Reports Health and Medicine Content

A new analysis method allows to find out the sex of the baby from the second month of pregnancy

next article
14.05.2008

Up to now it was necessary to wait until the forth or fifth month

 

The spin off of the University of Granada Lorgen, in collaboration with the Foetal Medicine Unit of the Maternity Hospital Virgen de las Nieves of Granada, has managed to develop a genetic trial that identifies the sex of the foetus from the eighth week of pregnancy separating the DNA found in the plasma of the pregnant woman.


This new finding has been tested through a clinical trial in 120 pregnant women, under the coordination Dr Sebastián Manzanares (Foetal Medicine Unit of the Virgen de las Nieves University Hospital). The method’s effectiveness rate is above 98%. Although the test can be carried out from the sixth week of pregnancy, the reliability of the technique is much higher from the eighth.
The technique is based on the fact that, during pregnancy, between 3.4 and 6.2% of the total DNA free in mother plasma has a foetal origin. Therefore, a simple peripheral blood sample is enough for the study, which opens new possibilities in the field of non-invasive prenatal diagnosis.

With all these privacy guarantees, the mother can carry out the extraction directly through a simple method, send it to Lorgen and receive the results 48 hours later.

Diagnosis of monogenic diseases
This new process, apart from saving the parents the wait until the forth or fifth month of pregnancy to find out the sex of their future baby, involves a great scientific progress with important medical applications; especially in the diagnosis of monogenic diseases related to X chromosome, such as haemophilia or Duchenne muscular dystrophy. In these cases, the possibility of determining the sex of the baby as soon as possible, would avoid the processes of invasive prenatal diagnosis such as amniocentesis, chorionic villus biopsy or cordcentesis, which involve a danger for the life of the foetus.

Genetic research and molecular biology
The research work has been sponsored by the Foundation for Biosanitary Research of Eastern Andalusia Alejandro Otero (FIBAO).

Lorgen GP is a pioneer company in the field of genetic research and molecular biology created as spin off of the University of Granada by Professor José Antonio Lorente Acosta, director of the Laboratory of Genetic Identification of the UGR.

Lorgen is one of the business initiatives sponsored by the investment holding of Granada Lider and made up by 24 businessmen and 2 financial entities (CajaGranada and Caja Rural de Granada).

Reference: Lorgen GP. Business Innovation Center – BIC/CEEI. Parque Tecnológico de Ciencias de la Salud. Avda. Innovación, 1. Armilla, Granada (Spain). Tel. 958 750 604. E-mail. info@lorgen.com.

Antonio Marín Ruiz | Source: alphagalileo
Further information: www.lorgen.com
prensa.ugr.es/prensa/research/index.php

next article

More articles from Health and Medicine:

nachricht Does hormone treatment predispose patients to breast cancer?
21.11.2008 | CNRS (Délégation Paris Michel-Ange)

nachricht Mechanisms of cardiovascular disease and cancer give clues to new therapies
21.11.2008 | European Science Foundation

B2B Search

Product / Service
Company / Organisation

Latest News

Sustainable garden roofs developed as a new construction material

21.11.2008 | Studies and Analyses

Bees declared the winners in Earthwatch’s ‘irreplaceable species’ battle

21.11.2008 | Ecology, The Environment and Conservation

Hairspray is linked to common genital birth defect

21.11.2008 | Studies and Analyses

Event News

The Automobile – The Transition from Energy Guzzler to Power Supplier

20.11.2008 | Event News

Ministers meet to define the role of space in delivering global objectives

18.11.2008 | Event News

156th Annual Acoustical Society of America (ASA) Meeting in Miami

28.10.2008 | Event News